Noting that it launched against “perhaps the most consequential backdrop imaginable for the overall Biotech industry,” today’s article examines the recent performance of the Nasdaq Junior Biotechnology Index (NBIJR) which, as its name suggests, focuses on smaller biotech companies – and thus “offers a less concentrated, but ultimately more speculative, way to track companies driving the future of the biotech industry.” For a look at the performance of the NBIJR since its April 30th launch, its current composition, and drivers of future performance, CLICK HERE.
“Imagine the market for an influenza vaccine that would not require modifications each year to address annual mutations in the influenza virus, that brings about immunity to strains of the influenza virus that do not even exist at the time of inoculation, and maintains immunity for at least four years,” requests the author of today’s article before proceeding to highlight a small biotech company with such a universal influenza vaccine candidate in the final stages of development – one which is very likely to successfully complete its pivotal Phase 3 trial by the end of October and be approved for market. For more on this small, undervalued biotech and its first-in-kind influenza vaccine, CLICK HERE.
The author of today’s article made a mistake when they previously went against their rules for trading a premium-priced biotech and jumped on a small-cap pharmaceutical stock focused on women’s health issues. Now, however, they see the stock as presenting a great contrarian opportunity. Here’s some of what they have to say: “The company had a rough time with the COVID-19 pandemic, but I believe it is primed to make a strong resurgence as the country opens up and the women’s health industry returns to normal operations.” For more, CLICK HERE.
“Given the volatile nature of biotech, many active traders look to the charts of popular exchange-traded products and their top holdings for clues as to the future direction of the segment,” notes the author of today’s article. As such, he proceeds to highlight “several charts from across the biotech space” in an effort to “determine how traders will be positioning themselves over the weeks and months ahead.” For more, CLICK HERE.
“The upside in biotech sector has been led by the small companies, primarily the ones developing a vaccine for coronavirus,” notes the author of today’s article, setting the stage for a look at five biotech stocks that have risen more than 100% so far this year (and way more than 100% in one case) – and which have seen positive earnings estimate revisions. For these five biotech stocks, CLICK HERE.
With the biotech space red-hot right now amid the race for solutions to the COVID-19 crisis, how can traders assess potential biotech plays? Noting that “biotechnology companies do not have traditional financial metrics”, the author of today’s article has “built a formula to help analyze them from a more potential based perspective” – and he shares this biotech valuation formula in a video. For more, CLICK HERE.
“One of the biggest advantages of options trading is that you can make money in any market. All you need is the right strategy to take advantage of the moment,” declares the author of today’s article, who proceeds to outline what one options trading specialist believes is the best strategy for this period of high uncertainty based on a historic pattern. For this options strategy – and the best options to take advantage of it now – CLICK HERE.
Today’s article highlights “a trio of biotech companies scheduled to make initial public offerings this week in what appears to be a favorable climate for new issues in the industry.” First up? A biopharmaceutical company focused on developing novel treatment options for patients with rare neurological disorders, and whose main product seeks to treat excessive daytime sleepiness in adults suffering from narcolepsy (a $1.8 billion market in the U.S.). For more on these three biotech IPOs, CLICK HERE.
After a week in which they came under pressure, what does the week ahead have in store for biotech stocks? Today’s article outlines the key biotech catalysts unfolding this week, from conferences and FDA approval decisions to earnings reports and IPOs. For more, CLICK HERE.
“Amid a relatively dry IPO year, biotech IPOs have boomed,” notes the author of today’s article, who proceeds to highlight what he believes are two of the best biotech IPOs to watch from here. One firm is a leader in developing a potential COVID-19 vaccine (and also has a number of other promising treatment candidates in clinical trials), and the other is focused on developing therapies for cancer and rare diseases. For more on these two biotech IPOs to watch, CLICK HERE.